Theracryf (TCF) Share Price, News & Analysis

Company Overview

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy. The company has a partnership with Stalicla to collaborate on a clinical program in autism spectrum disorder. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Key Stats

• Today's Range: 0.56 to 0.65
• 50-Day Range: 0.60 to 0.80
• 52-Week Range: 0.56 to 1.05
• Volume: 285,014 shs
• Average Volume: N/A
• Market Capitalization: £2.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCF Stock Analysis - Frequently Asked Questions

How have TCF shares performed this year?

Theracryf's stock was trading at GBX 0.65 at the beginning of the year. Since then, TCF stock has decreased by 7.7% and is now trading at GBX 0.60.
View the best growth stocks for 2024 here.

How do I buy shares of Theracryf?

Shares of TCF stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Banking
• Current Symbol: LON:TCF
• CUSIP: N/A
• CIK: N/A
• Web: theracryf.com
• Phone: 44-1625-315-090
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,140,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -81.67%
• Return on Assets: -48.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.19
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: GBX 1 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 427,350,000
• Free Float: N/A
• Market Cap: £2.56 million
• Optionable: N/A
• Beta: 1.42